Research Article

Dyslipidemia in Patients with a Cardiovascular Risk and Disease at the University Teaching Hospital of Yaoundé, Cameroon

Vicky Jocelyne Ama Moor, Sylvie Ndongo Amougou, Sebastien Ombotto, Felicien Ntone, Doriane Edna Wouamba, and Bernadette Ngo Nonga

1Department of Biochemistry, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon
2Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon
3Institute of Medical Technology, Yaoundé, Cameroon
4Department of Surgery, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon

Correspondence should be addressed to Bernadette Ngo Nonga; ngonongab@yahoo.com

Received 1 June 2016; Revised 4 October 2016; Accepted 15 December 2016; Published 9 January 2017

Academic Editor: Thomas Schmitz-Rixen

Copyright © 2017 Vicky Jocelyne Ama Moor et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To determine the frequency of lipid abnormalities in patients with a cardiovascular risk and disease at the University Teaching Hospital (UTH) of Yaoundé. Materials and Methods. We conducted a cross-sectional study from 1 March to 31 May 2015 at the UTH of Yaoundé. We included all patients seen in the outpatient department with a diagnosis of a cardiovascular disease or a risk factor for cardiovascular disease. Patients who accepted to participate in the study were asked to answer a questionnaire; after that a blood sample was taken for lipid profile. An informed consent was signed by all the participants and the study has received approval from the national ethic committee. Results. We recruited 264 patients of which 119 were men and 145 were women with a sex ratio of 0.82. Mean age was 61.36 years. The frequency of lipid profiles abnormalities was as follows: low HDL cholesterol (44.3%), hypertriglyceridemia (18.9%), high LDL cholesterol (3.8%), and high total cholesterol 3.4%). Hypertriglyceridemia was strongly associated with type 2 diabetes mellitus. Conclusion. Low levels of HDL cholesterol and hypertriglyceridemia are more prevalent in our study population. More studies are needed to confirm this finding in our environment.

1. Introduction

Cardiovascular diseases involve the cardiovascular system: heart, blood vessels, and the circulatory system [1]. They represent the first cause of invalidity in developed countries. According to World Health Organization, the prevalence of cardiovascular diseases will double by 2020 and will rank before the HIV/AIDS infection [2].

One of the major risk factors of cardiovascular diseases is arteriosclerosis which is secondary to the excess of LDL cholesterol. Clinical manifestations of arteriosclerosis are found in coronary artery disease, ischemic stroke, and peripheral vascular occlusive diseases. Dyslipidemia is a metabolic abnormality leading to a persistent increase in the plasmatic concentration of cholesterol and triglycerides. There are currently three types of dyslipidemia, hypercholesterolemia, hypertriglyceridemia, and mixed hyperlipidemia, due to elevation of both cholesterol and triglycerides [3]. Dyslipidemia is a common cause of morbidity all over the world, and the most common form is hypercholesterolemia defined as a total cholesterol level above 5.0 mmol/L or 190 mg/L. One-third of ischemic heart diseases in the world are secondary to hypercholesterolemia, and it is estimated that hypercholesterolemia is responsible for 2.6 million (4.5%) deaths in the world [4]. In 2008, the worldwide prevalence of hypercholesterolemia in western countries was 39% in males and 40% in females [5]. In Cameroon, very few studies have been conducted to determine the frequency of the dyslipidemias in our environment.

The objective of this study was to determine the prevalence of lipid profile abnormalities in patients presenting with a cardiovascular disease or risk factor at the University Teaching Hospital of Yaoundé, Cameroon.
2. Patients and Methods

2.1. Patients. We carried out a cross-sectional study from March to May 2015 at the University Teaching Hospital (UTH) of Yaoundé. The study included all patients with a cardiovascular disease seen at the UTH during that period: ischemic heart disease, stroke, peripheral vascular disease, hypertension, and cardiomyopathies; we also included patients with a risk factor for cardiovascular disease such as diabetes mellitus. All patients were informed about the protocol and if they accepted to participate in the study, they were asked to sign a consent before enrollment. We excluded patients with an incomplete file and hemolyzed blood serum and those who refused to participate in the study.

2.2. Methods. Patients were given a questionnaire administered by the investigators. The questionnaire was first administered to 16 nonmedical persons accompanying patients at the emergency department as a pretest and validated. Collected data were sociodemographic information (age and sex,) and cardiovascular risk factors and diseases. Blood was drawn by the same person who respected the appropriate recommendations before the determination of plasma lipid's abnormalities.

The first phase was the preanalytical phase: patients were asked to fast for 12 hours before blood was drawn. The elbow was cleaned and blood was taken in a tube without anticoagulant; we use a loose vein occlusion to minimize the risk of hemolysis. Specimens were taken to the laboratory in less than 20 minutes after the procedure in a specific box.

The tubes were centrifuged at 3000 rpm for 5 minutes before preservation.

Our judgment criteria for a dyslipidemia were as follows [6]:

- Total cholesterol > 2.70 g/L
- HDL cholesterol < 0.44 g/L
- LDL cholesterol > 1.88 g/L
- Triglycerides > 1.50 g/L

Analysis was done using the CYAN START photometer of the CYPRESS Laboratory (Langdorp, Belgium). Total cholesterol, HDL cholesterol, and triglycerides were determined using an enzymatic method found in commercial kits of the CYPRESS Laboratory (Langdorp, Belgium); LDL cholesterol was calculated using the formula of Friedewald (1972) [7]. Results were validated using a quantitative control serum.

2.3. Statistical Analysis. Data were encoded using the CS Pro software version 4.1. Statistical analysis was done using Epi Info 3.54 software and represented in tables using the Microsoft Excel 2010 software. Statistical test used was chi square. Difference was found to be significant if $P < 0.05$.

2.4. Ethical Considerations. The study has obtained ethical clearance from the national ethic committee of Cameroon (number CEI-UD/246/02/2015/T). Informed consent was obtained before enrollment in the study.

3. Results

3.1. Sociodemographic Characteristics of the Patients. During that period, 596 patients with a cardiovascular disease or risk factors were seen at the UTH, of which 350 met the inclusion criteria and accepted to participate in the study. Because of poverty, only 264 were able to have a lipid profile done and 86 patients were then excluded because of incomplete file. The population of the study composed of 264 patients of which 119 (45.1%) were men and 145 (54.9%) were women, giving a sex ratio of 0.81. The mean age was 61.36 years with a minimum of 32 years and a maximum of 88 years. The most common age group was between 50 and 60 years and represented 36% of patients.

3.2. Risk Factors for Cardiovascular Disease and Life Style. Sedentariness was found in 188 (71%) patients, 142 (53.7%) patients drank alcohol regularly, obesity was found in 74 (27.9%) patients, 19 (71%) patients were smokers, hypertension was found in 169 (64%) patients, and 43 (16.3%) patients had diabetes mellitus. The association of hypertension and diabetes mellitus was found in 29 patients (10.98%).

3.3. Cardiovascular Pathologies. The most common cardiovascular disease was hypertension found in 169 patients (64%), followed by stroke found in 35 patients (13.25%), ischemic heart diseases in 14 patients (5.3%), and other cardiomyopathies in 16 patients (6.06%). One patient had deep venous thrombosis.

3.4. Abnormalities of the Lipid Profile. The results of the lipid profile in the 264 patients are shown in Table 1: only 9 patients (3.4%) had high total cholesterol levels, 10 (3.8%) patients had a higher than normal LDL cholesterol, and 50 (18.9%) had above normal triglycerides levels, giving prevalence of dyslipidemia of 26%.

Mean total cholesterol levels and LDL cholesterol levels were higher in women than in men and this difference was significant ($P = 0.01$ and $P = 0.03$, resp.) (Table 1), while mean HDL cholesterol and triglycerides were also higher in
Table 2: Comparison of the lipid profile in men and women.

| Lipid          | Sex   | Mean levels | Lowest | Maximum | Standard deviation | P value |
|----------------|-------|-------------|--------|---------|--------------------|---------|
| Total cholesterol | Male  | 1.78g/L     | 0.69g/L| 2.99g/L | 0.43               | P = 0.01|
|                | Female| 1.90g/L     | 0.93g/L| 3.37g/L | 0.44               |         |
| HDL cholesterol | Male  | 0.46g/L     | 0.14g/L| 1.26g/L | 0.18               | P = 0.14|
|                | Female| 0.49g/L     | 0.13g/L| 1.22g/L | 0.19               |         |
| LDL cholesterol | Male  | 1.09g/L     | 0.11g/L| 2.4g/L  | 0.42               | P = 0.03|
|                | Female| 1.18g/L     | 0.2g/L | 2.55g/L | 0.39               |         |
| Triglycerides  | Male  | 1.13g/L     | 0.40g/L| 3.05g/L | 0.52               | P = 0.7 |
|                | Female| 1.15g/L     | 0.31g/L| 4.33g/L | 0.55               |         |

Table 3: Distribution of dyslipidemia in patients with a low HDL cholesterol.

| LDL | Low | Normal | High | Total |
|-----|-----|--------|------|-------|
| Low | 14  | 12     | 11   | 37    |
| Normal | 28  | 26     | 22   | 76    |
| High | 1   | 2      | 1    | 4     |
| Total | 43  | 40     | 34   | 117   |

Table 4: Distribution of dyslipidemia in patients with a normal level of HDL cholesterol.

| LDL | Low | Normal | High | Total |
|-----|-----|--------|------|-------|
| Low | 32  | 14     | 7    | 53    |
| Normal | 37  | 27     | 8    | 72    |
| High | 1   | 5      | 0    | 6     |
| Total | 70  | 46     | 15   | 131   |

Table 5: Distribution of dyslipidemia in patients with a high HDL cholesterol.

| LDL | Low | Normal | High | Total |
|-----|-----|--------|------|-------|
| Low | 6   | 3      | 1    | 10    |
| Normal | 4   | 2      | 0    | 6     |
| Total | 10  | 5      | 1    | 16    |

Comparing women to men, this difference was not statistically significant (Table 2). Based on the definition of dyslipidemia, the most common abnormality was hypertriglyceridemia (18.90%) followed by LDL hypercholesterolemia (3.8%) and total hypercholesterolemia (3.4%). Low level of HDL cholesterol was found in 117 (44.3%) patients (Table 3): 35 patients were on statin medications (anticholesterol drugs); the remaining 82 patients were not on any anticholesterol drugs. Low HDL and low LDL cholesterol were simultaneously present in 37 (31.62%) patients from 117 who had low HDL cholesterol (Table 3). These patients were considered to have low risk lipid profile. If we consider low HDL cholesterol as a dyslipidemia, 149 of the patients were having a lipid abnormality, giving corrected prevalence of 56.4% for a dyslipidemia in our study. Only one patient had high LDL cholesterol and low HDL and he was considered to have high risk lipid profile. In this group, 4 patients (3.4%) had atherogenic dyslipidemia (low HDL and elevated LDL or triglycerides) (Table 3).

From 131 (49.6%) patients who had a normal HDL cholesterol, 32 (24.4%) had also low LDL and triglycerides level, 27 (20.61%) had normal LDL and TG levels, 6 (4.58%) had a normal HDL and an elevated LDL, and 15 (11.45%) had elevated triglycerides. There was no mixed dyslipidemia in this study (Table 4).

Sixteen (6%) patients had a high HDL cholesterol, of which 6 (37.5%) had an elevated LDL and a low triglyceride level, 2 (12.5%) had normal LDL and triglycerides, and one had elevated triglycerides with a low LDL and high HDL (Table 5).

Regarding atherogenic index (total cholesterol/HDL cholesterol), 95 (36%) of our patients had an index of more than 4.5 and 169 (64%) had an index below 4.5.

There was a strong association between diabetes mellitus and hypertriglyceridemia (odds ratio = 2.73 and P = 0.003).

Low HDL cholesterol level and hypertriglyceridemia were more frequent in patients with hypertension (74.4% and 84%, resp.). It was the same in patients with diabetes mellitus (11.1% and 18%).

4. Discussion

Considering low HDL cholesterol or hypocholesterolemia HDL as a risk factor we have found prevalence of dyslipidemia in our patients with a cardiovascular risk or disease of 56.4%, with 36% of the patients having an elevated atherogenic index of more than 4.5. Dyslipidemia would then be the fourth risk factor for cardiovascular disease as reported by Karaye et al. in Nigeria [8].

Levels of total, HDL, and LDL cholesterol and TG were more elevated in women than in men, although our values were lower than the ones reported by Youmbissi et al. in 2001 [9]. This difference may be due to the difference in the number of patients (we have a larger number of patients) and also Youmbissi et al. studied only patients with hypertension. Thirty-five of the patients were on anticholesterol medications which may have contributed to the increase of the
number of patients with low HDL cholesterol and low LDL cholesterol at the same time. High levels of abnormal lipid profile in women compared to men have also been reported in Nigeria [10]. Mean triglycerides levels in our study were lower than the ones reported from Gabon [11] and mean values of HDL cholesterol were lower than the ones reported by Youmbissi et al. from Cameroon [9].

The most common lipid abnormality was low HDL cholesterol, followed by elevated triglycerides and elevated LDL cholesterol, with high level of total cholesterol being the last one. All these values were more elevated in women than in men. This result is different from the one reported by Apetse et al. from Togo who found total hypercholesterolemia followed by LDL hypercholesterolemia and the hypertriglyceridemia to be the most common lipid abnormalities in patients with stroke [12]. A study in urban New Delhi has shown prevalence of low HDL-C of 37% in the studied population, which was very close to our findings of 44%, as reported by Chandra et al. [13].

In our study, in patients with hypertension, hypercholesterolemia HDL was the most common lipid abnormality unlike Youmbissi et al. who have found that hypercholesterolemia was the most common abnormality followed by hypertriglyceridemia and mixed hyperlipidemia [9]. Tiahou et al. from Ivory Coast found also hypercholesterolemia as the most common lipid abnormality [14] but they carried out a study in all patients who have done a lipid profile at the University Hospital of Cocody during that period and did not consider low HDL cholesterol as an abnormality.

The prevalence of total hypercholesterolemia was 3.4% of patients, which is lower than the one reported by Ndiaye et al. from Senegal (52.34%) in patients with an ischemic stroke; this prevalence is also lower than the one reported by Maiga from Mali in patients with hypertension (23.26%) and the one reported by Goudot from Senegal in patients with coronary artery diseases (19.6%) [15–17]. Hypercholesterolemia is the most common abnormality in patients from Senegal and Ivory Coast [2, 14].

Hypercholesterolemia LDL was found only in 3.8% of our patients; this is very low compared to the percentage found by Apetse et al. in patients with a stroke which was 47.96% in Togo [12] and it is also low compared to the one found by Doupa et al. which was 22.5% in Senegal [2]. We have reported this finding in a previous study, where we have found that hypercholesterolemia was uncommon in patients with ischemic stroke in association with low prevalence of significant carotid stenosis [18]. Rather than hypercholesterolemia in high risk patients, we have found hypocholesterolemia HDL to be very high in our study population and this was the most common abnormality found in 44.3% of the patients. Hypcholesterolemia HDL has been also found to be common in Nigeria in a group of patients with cardiovascular risks as reported by Umar et al. [19]. Gonzalez-Pacheco et al. have also reported a high percentage of patients with hypocholesterolemia HDL (68.6%) in patients with acute coronary syndrome in Mexico [20]. The low level of HDL cholesterol may be due to antilipid medication (only 35 patients were taking anticholesterol medication); we believe that this low HDL cholesterol is a common finding in the lipid profiles of patients in our environment. Low levels of HDL cholesterol are as common as high levels of LDL cholesterol as has been reported in one study in which low level of HDL was the most common abnormality of lipid profile found in the population [21]; although low HDL-C is considered as a dyslipidemia and elevated HDL-C has been found to have cardiovascular protective effect, little is known about the exact clinical relevance of low HDL-C [22].

In general, low levels of HDL cholesterol in human are secondary to type 2 diabetes mellitus and the metabolic syndrome because of the increase catabolism due to hypertriglyceridemia [21]. There are other reported causes of low level of HDL: sedentariness, low fat diet, medications, and drugs; genetic abnormalities are less common [21]. In one study, low HDL cholesterol in association with hypertriglyceridemia has been found in 8% of the patients [23]. The atherogenic index is high when the HDL is low; 36% of our patients had an elevated atherogenic index and 44.3% had a very low HDL level, making us state that low HDL should also be considered as a risk factor for cardiovascular disease in Cameroon as reported [24, 25]. Elevated LDL which is a well-known risk factor is low in our country, while low HDL which is equally a recognized factor is more prevalent.

Hypertriglyceridemia was present in 18.9% of our patients which is more than the prevalence found by Nissee et al. in Tunisia which was 13.6% [23] and this was lower than the 25% found by Sumner et al. in their patients with a metabolic syndrome [26].

There was a strong association between diabetes and hypertriglyceridemia as has been found by Lokrou in Ivory Coast [27]. There was no association between tobacco and hypertriglyceridemia or alcohol and hypertriglyceridemia as has been reported by Abessolo et al. in Gabon [28].

5. Conclusion
In this population with cardiovascular risk factors and diseases, the most common lipid abnormality was low HDL cholesterol. Few patients presented elevated LDL cholesterol compared to the literature, making hypercholesterolemia be considered as a less common cardiovascular risk factor compared to hypertension and low HDL cholesterol which were very common. We would recommend multicenter studies and population based studies to further assess this important finding.

Competing Interests
The authors declare that there are no competing interests regarding the publication of this paper.

Authors’ Contributions
Bernadette Ngo Nonga, Vicky Jocelyne Ama Moor, and Sylvie Ndongo Amougou contributed to the design of the study. Doriane Edna Wouamba and Vicky Jocelyne Ama Moor contributed to the realization of the study. Bernadette
Ngo Nonga and Doriane Edna Wouamba contributed to data analysis. Bernadette Ngo Nonga, Felicien Ntone, and Sebastien Ombotto contributed to the supervision of the study.

References

[1] Fondation des Maladies du Cœur du Québec, *Statistiques*, 2010.
[2] D. Doupa, S. M. Seck, C. A. Dia et al., "Dyslipidemia, obesity and other cardiovascular risk factors in the adult population in Senegal," *Pan African Medical Journal*, vol. 19, article no. 181, 2014.
[3] AFSSAP (Agence Française de Sécurité Sanitaire des Produits de Santé), "Prise en charge thérapeutique du patient dyslipidémique," *Argumentaire*, pp. 3–5, 2005.
[4] OMS, *Cadre Global Mondial de Suivi, Comprendant des Indicateurs, et Série de Cibles Mondiales Volontaires Pour la Lutte Contre les Maladies non Transmissibles*. OMS, Geneva, Switzerland, 2012.
[5] OMS, *Rapport sur la Situation Mondiale des Maladies non Transmissibles (Résumé d’Orientation) 2010*, OMS, Geneva, Switzerland, 2011.
[6] T. J. Youmbissi, S. Djoumessi, J. Simo Moyo, C. Noudoulou, C. Tchemo, and E. C. Zam Ngono, "Profil lipidique général d’un groupe de malades insuffisants rénaux chroniques camerounais," *Médecine d’Afrique Noire*, vol. 41, no. 1, 1994.
[7] W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, "Estimation of concentration of low density lipoprotein cholesterol in plasma without use of ultracentrifuge," *Clinical Chemistry*, vol. 18, pp. 499–502, 1972.
[8] K. M. Karaye, I. Nashabaru, G. M. Fika et al., "Prevalence of traditional cardiovascular risk factors among Nigerians with stroke," *Cardiovascular Journal of Africa*, vol. 18, no. 5, pp. 290–294, 2007.
[9] T. J. Youmbissi, S. Djoumessi, C. Noudoulou, P. Ndbo, and J. Meli, "Profil Lipidique d’un Groupe d’Hypertendus Camerounais Noirs Africains," *Médecine d’Afrique Noire*, vol. 48, no. 7, pp. 305–314, 2001.
[10] J. O. Idemudia and E. I. Ugwuja, "Plasma lipid profiles in hypertensive Nigerians," *The Internet Journal of Cardiovascular Research*, vol. 6, no. 2, 2009.
[11] E. Ngou-Milama, A. Llamidi, R. Makandja, M. Methogo, B. Moundounga, and B. Okomo, "Valeurs de référence du cholestérol total, des triglycérides, de l'apolipoprotéine A1, de l'apolipoprotéine B et de la Lp(a) dans la population gabonaise. Etude sur 1020 sujets," *Bulletin Médical d'Owendo*, vol. 18, pp. 60–61, 1997.
[12] K. Apetse, M. Matelbe, K. Assogba et al., "Prévalence de la dyslipidémie, de l’hyperglycémie et de l’hyperuricémie chez les patients victimes d’AVC au Togo," *African Journal of Neurological Sciences*, vol. 30, no. 1, 2012.
[13] K. S. Chandra, M. Bansal, T. Nair et al., "Consensus statement on management of dyslipidemia in Indian subjects," *Indian Heart Journal*, vol. 66, supplement 3, pp. S1–S51, 2014.
[14] G. Tiahou, K. Deret, A. Monde, M. Gniwo Camara-Cisse, and Y. Djoh, "Fréquence des bilans lipidiques et prévalence des dyslipidémies au Laboratoire de biochimie du CHU de Cocody," *Journal des Sciences Pharmaceutiques et Biologiques*, vol. 11, no. 2, pp. 60–65, 2010.
[15] M. Ndiaye, S. M. I. Dadah, L. B. Seck et al., "Profil lipidique et glucidique des AVCI à la clinique de neurologie du CHNU de fann," in *Proceedings of the 9ème Congrès International Francophone de la Société de Pathologie Exotique, UCAD, Dakar, Senegal*, 2013.
[16] A. Maiga, Dépistage des facteurs de risque Cardiovasculaires (dyslipidémies et Hyperglycémie) au centre de santé de Référence de la commune V et au CHU Gabriel TOURE (thèse de médecine) [Ph.D. thesis], Université de Bamako, Faculté De Médecine, De Pharmacie et Dodontostomatologie, Bamako, Mali, 2009.
[17] P. Y. Goudoue, *Les infarctus du myocarde thrombolysés: a propos de 36 cas au service de réanimation de l’hôpital principal de Dakar [Thèse de Médecine], Faculté De Médecine, De Pharmacie Et Dodontostomatologie, Bamako, Mali, 2003.
[18] B. Ngo Nonga, J. C. Mbala, N. Felicien et al., "Prevalence of significant carotid stenosis and other risk factors in patients with acute ischemic stroke in Yaounde, Cameroon," *Journal of Vascular Medicine & Surgery*, vol. 4, article 257, 2016.
[19] G. A. Umar, A. G. Okuku, O. C. Oladele, J. J. Aisha Oduh, and F. J. Abidemi, "Profil lipidique sérique et corrélation chez des patients Nigérians récemment hypertendus," *Vase Manag Risques Pour la Santé*, vol. 9, pp. 763–768, 2013.
[20] H. Gonzalez-Pacheco, M. Vallejo, A. Altamirano-Castillo et al., "Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease," *Therapeutics and Clinical Risk Management*, vol. 10, pp. 815–823, 2014.
[21] W. F. Riesen and M. Hug, "HDL bas—haut risque, HDL haut—faible risque?" *Forum Médical Suisse*, vol. 8, no. 14, pp. 246–252, 2008.
[22] M. Vergeer, A. G. Holleboom, J. J. P. Kastelein, and J. A. Kuivenhoven, "The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?" *Journal of Lipid Research*, vol. 51, no. 8, pp. 2058–2073, 2010.
[23] B. A. Nissaf, D. Francis, and B. R. Habiba, "Modèle causal des cardiopathies ischémiques en Tunisie," *Options Méditerranéennes Série B*, no. 41, p. 14, 2002.
[24] M. D. Ashen and R. S. Blumenthal, "Low HDL cholesterol levels," *The New England Journal of Medicine*, vol. 353, no. 12, pp. 1252–1260, 2005.
[25] C. Besler, T. F. Lüscher, and U. Landmesser, "Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease," *EMBO Molecular Medicine*, vol. 4, no. 4, pp. 251–268, 2012.
[26] A. E.Sumner, J. Zhou, A. Doumatey et al., "Low HDL-cholesterol with normal triglyceride levels is the most common lipid pattern in West Africans and African Americans with metabolic syndrome: implications for cardiovascular disease prevention," *CVD Prevention and Control*, vol. 5, no. 3, pp. 75–80, 2010.
[27] A. Lokrou, "Hyperlipidemie et Diabète en Côte d’Ivoire: Etude transversale de 132 cas," *Médecine d’Afrique Noire*, vol. 45, no. 10, p. 123, 1998.
[28] F. Abessolo, S. Bekale, F. Jose, Y. Moutsinga, and E. Milama, "Profil lipidique, cinétique d’apparition des diènes conjugués et activité paraoxonase-1 chez le diabétique de type 2 à Libreville au Gabon," *International Journal of Biological and Chemical Sciences*, vol. 6, no. 2, pp. 572–581, 2012.